Tamoxifen Therapy for Breast Cancer with Drs. Stephen Edge and Gokul Das

PrintE-mail
Sunday, February 10, 2013

New research has highlighted the effectiveness of long-term treatment with tamoxifen, the first targeted therapy to be approved for treatment of breast cancer, for many patients with the disease. Stephen Edge, MD, Alfiero Foundation Endowed Chair in Breast Oncology, and Gokul Das, PhD, Co-Director of RPCI's Breast Disease Site Research Group, discuss these recent findings as well as their ongoing clinical study, still recruiting new patients, to determine which patients will respond best to this important endocrine therapy.

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Cancer Can't Win

More patients are being diagnosed with cancer every day.

Here at Roswell Park Cancer Institute, we must continue to do what we do best – to understand, prevent and cure cancer. Because if we don’t, cancer wins. And Cancer Can’t Win.

  • With more than 3,000 scientific, academic and medical minds – Cancer Can’t Win.
  • When we are leading an advanced genetic program and creating next generation cancer vaccines to prevent it – Cancer Can’t Win.
  • When we are starting 13 new companies to advance our discoveries and share them with the world – Cancer Can’t Win.

Learn more about why Cancer Can’t Win

close